搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
9 小时
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
4 小时
on MSN
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
https//insights.som.yale.edu
5 小时
What Critics of Pfizer Are Getting Wrong
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
2 天
on MSN
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
BioPharma Dive
1 小时
Pfizer drug for hemophilia approved by FDA
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
6 小时
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
2 天
on MSN
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
FiercePharma
4 小时
BMS, Pfizer, Regeneron, Cardinal Health and more back ‘enhanced’ thrombosis awareness ...
All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...
腾讯网
1 天
首款!每周一次,辉瑞长效血友病疗法获FDA批准
▎药明康德内容团队编辑今天,美国FDA批准辉瑞(Pfizer)药品Hympavzi(marstacimab)用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血,这些患者体内不含凝血因子VIII与IX抑制剂(中和抗体)。根据新闻稿, ...
2 天
首款每周一次长效血友病疗法获FDA批准 来自辉瑞
当地时间10月11日,美国FDA批准辉瑞(Pfizer)药品Hympavzi(marstacimab)用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血,这些患者体内不含凝血因子VIII与IX抑制剂(中和抗体)。
wap.stockstar
16 小时
21健讯Daily|市场监管总局发布《医药企业防范商业贿赂风险合规指引 ...
10月11日,黑龙江省医保局官微曝光了3例违法违规使用医疗保障基金的典型案例,涉及串换项目收费、重复收费、超标准收费、过度检查、将不属于医疗保障基金支付范围的医药费用纳入医疗保障基金结算等违法违规行为。
12 小时
【中航证券医药】行业周报 | 震荡中成长,把握后续分化行情
从近期医药板块及指数走势来看,行业经历了较大幅度的震荡,但仍表现出较为明显的触底反弹趋势。短期来看,我们认为行业仍将在震荡中上行,在受到市场情绪波动和外部因素干扰等因素下,行业短期内或将呈现出进二退一的上行趋势。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈